Edition:
India

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

32.44USD
12:37am IST
Change (% chg)

$-0.20 (-0.61%)
Prev Close
$32.64
Open
$32.44
Day's High
$32.78
Day's Low
$32.33
Volume
614,546
Avg. Vol
1,583,369
52-wk High
$55.79
52-wk Low
$27.59

TEVA.N

Chart for TEVA.N

About

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic... (more)

Overall

Beta: 0.46
Market Cap(Mil.): $32,966.30
Shares Outstanding(Mil.): 1,014.36
Dividend: 0.34
Yield (%): 4.17

Financials

  TEVA.N Industry Sector
P/E (TTM): 308.94 13.56 17.15
EPS (TTM): 0.11 -- --
ROI: 0.52 -7.26 -5.60
ROE: 0.27 -6.80 -4.89

BRIEF-Teva announces launch of generic vagifem in U.S.

* Teva announces the launch of generic vagifem in the United States

12:23am IST

Teva Pharm to reduce workforce in Israel, mainly in production

TEL AVIV, July 23 Teva Pharmaceutical Industries said on Sunday it would lay off some of its 7,000 employees in Israel in the coming months as it reorganises in a drive to improve competitiveness.

23 Jul 2017

UPDATE 2-EU regulators charge Teva over pay-for-delay drug deal

BRUSSELS, July 17 EU antitrust regulators charged Israeli drugmaker Teva on Monday with doing an illegal deal with Cephalon to delay selling a cheaper generic version of the latter's sleep disorder drug, putting it at risk of a fine.

17 Jul 2017

BRIEF-Teva Pharm denies anti-competitive behavior with Cephalon

* Said on Monday it does not believe it entered into "any anti-competitive behavior" with Cephalon.

17 Jul 2017

EU regulators charge Teva over pay-for-delay drug deal

BRUSSELS, July 17 EU antitrust regulators charged Israeli drugmaker Teva on Monday with doing an illegal deal with Cephalon to delay selling a cheaper generic version of the latter's blockbuster sleep disorder drug.

17 Jul 2017

Fitch Revises Glenmark's Outlook to Stable; Affirms at 'BB'

(The following statement was released by the rating agency) SINGAPORE/MUMBAI, July 14 (Fitch) Fitch Ratings has revised Glenmark Pharmaceuticals Ltd's (Glenmark's) Outlook to Stable from Positive, and affirmed the Long-Term Issuer Default Rating (IDR) at 'BB'. The agency also affirmed the rating on Glenmark's USD200 million 4.50% senior unsecured notes due 2021 at 'BB'. The revision in the Outlook reflects Fitch's expectation that Glenmark's free cash flow will be largely neutral over the next t

14 Jul 2017

UPDATE 1-AstraZeneca's CEO Soriot to join Israeli drugs company Teva-report

TEL AVIV, July 12 Israel-based Teva Pharmaceutical Industries is expected to name Anglo-Swedish group AstraZeneca's Chief Executive Pascal Soriot as Teva's next CEO, the Calcalist financial news website said on Wednesday.

13 Jul 2017

AstraZeneca's CEO Soriot to join Israeli drugs company Teva-report

TEL AVIV, July 12 Israel-based Teva Pharmaceutical Industries will name AstraZeneca chief executive Pascal Soriot as its next CEO, the Calcalist financial news website said on Wednesday.

13 Jul 2017

BRIEF-Celltrion and Teva announce FDA acceptance of BLA for CT-P10

* Celltrion and teva announce u.s. Fda acceptance of biologics license application for proposed biosimilar to rituxan® (rituximab)

29 Jun 2017

BRIEF-Teva pharmaceutical publishes results of aim-td study in lancet psychiatry

* Publication of AIM-TD study results in lancet psychiatry for investigational use of deutetrabenazine in tardive dyskinesia​ Source text for Eikon: Further company coverage:

29 Jun 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF79.55 -0.75
Biogen Inc (BIIB.OQ) $284.69 +1.77

Earnings vs. Estimates